Beta Bionics (NASDAQ:BBNX – Get Free Report) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it weigh in compared to its competitors? We will compare Beta Bionics to similar businesses based on the strength of its institutional ownership, dividends, analyst recommendations, valuation, risk, profitability and earnings.
Analyst Ratings
This is a breakdown of recent recommendations for Beta Bionics and its competitors, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Beta Bionics | 1 | 4 | 9 | 1 | 2.67 |
| Beta Bionics Competitors | 4257 | 10483 | 18210 | 824 | 2.46 |
Beta Bionics presently has a consensus target price of $23.69, suggesting a potential upside of 41.45%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 25.78%. Given Beta Bionics’ stronger consensus rating and higher possible upside, analysts plainly believe Beta Bionics is more favorable than its competitors.
Risk and Volatility
Beta Bionics has a beta of 3.44, suggesting that its stock price is 244% more volatile than the S&P 500. Comparatively, Beta Bionics’ competitors have a beta of 2.57, suggesting that their average stock price is 157% more volatile than the S&P 500.
Insider and Institutional Ownership
40.6% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 5.3% of Beta Bionics shares are held by insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Beta Bionics and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Beta Bionics | -65.31% | -27.33% | -24.28% |
| Beta Bionics Competitors | -278.23% | -150.06% | -21.87% |
Earnings & Valuation
This table compares Beta Bionics and its competitors gross revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Beta Bionics | $100.25 million | -$73.20 million | -9.10 |
| Beta Bionics Competitors | $1.89 billion | $138.79 million | 10.75 |
Beta Bionics’ competitors have higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Summary
Beta Bionics beats its competitors on 7 of the 13 factors compared.
Beta Bionics Company Profile
Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.
Receive News & Ratings for Beta Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beta Bionics and related companies with MarketBeat.com's FREE daily email newsletter.
